[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362644-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362644-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","unique-features-of-a-comprehensive-genomic-profiling-panel-expanding-treatment-options-in-a-value-based-community-oncology-network-original-reports-precision-medicine","Unique Features of a Comprehensive Genomic Profiling Panel - Expanding Treatment Options in a Value-Based Community Oncology Network - Original Reports - Precision Medicine","","Comprehensive genomic profiling (CGP) is recommended to tailor precision-guided cancer therapies, yet existing guidance often does not specify which panel features and sizes matter most. This pilot pan-cancer study evaluated patients treated in a value-based community oncology setting who received NGS-based CGP and expanded analyses of de-identified records. Potentially actionable alterations were identified more often with advanced features than with standard in-network testing.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/unique-features-of-a-comprehensive-genomic-profiling-panel-expanding-treatment-options-in-a-value-based-community-oncology-network-original-reports-precision-medicine/362644/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/unique-features-of-a-comprehensive-genomic-profiling-panel-expanding-treatment-options-in-a-value-based-community-oncology-network-original-reports-precision-medicine/362644.png","ImageObject",300,407,{"name":42,"@type":43},"Taylor Morgan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is comprehensive genomic profiling (CGP) considered important for cancer treatment?","Question",{"text":63,"@type":64},"CGP is advocated to tailor precision-guided therapies for patients with cancer. It helps identify genomic biomarkers linked to FDA-approved treatments.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study assess the impact of CGP panel features?",{"text":68,"@type":64},"The study used a pilot pan-cancer cohort receiving NGS-based CGP and an expanded analysis of de-identified patient records. It evaluated potentially actionable findings, including those detected only by advanced features.",{"name":70,"@type":61,"acceptedAnswer":71},"Which advanced CGP features contributed to improved detection of actionable findings?",{"text":72,"@type":64},"Tumor-normal matching, RNA sequencing, and liquid biopsy reflex testing were identified as key features that found actionable alterations not detected by existing in-network NGS options.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362644,1790661529,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Original Reports | Precision Medicine  \nUnique Features of a Comprehensive Genomic Profiling Panel: Expanding Treatment Options in a Value-Based Community Oncology Network  \nPaul La Porte, MD, PhD1; Arya Ashok, PhD2  ; Nathan W. Sweeney, PhD2  ; Dana F. DeSantis, PhD2  ; Calvin Chao, MD2,3  ; Omkar Marathe, MD4; and Ezra E.W. Cohen, MD2  \nDOI [https://doi.org/10.1200/PO-25-00623](https://doi.org/10.1200/PO-25-00623)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | Comprehensive genomic profiling (CGP) is strongly advocated by organizations like ASCO and National Comprehensive Cancer Network (NCCN) to tailor precision-guided therapies for patients with cancer. However, these guidelines often lack specificity regarding panel size or essential features required within CGP panels. |\n| MATERIALS\u003Cbr>AND METHODS | A pilot pan-cancer study of patients (N 5 85) treated in a value-based community health care setting who received next-generation sequencing (NGS)– based CGP from Tempus AI, Inc and an expanded analysis of de-identified patient records from the Tempus database (N 5 465) for patients treated within a community health care network. Rates of potentially actionable findings defined as variants matching US Food and Drug Administration –approved therapies (somatic variants/resistance markers, Tumor Mutational Burden high [TMB-H] or Microsatellite Instability high [MSI-H]), or identification of pathogenic/likely pathogenic germline findings. Enrollment in clinical trials was included in the expanded cohort. |\n| RESULTS | In our pilot cohort, potentially actionable alterations were detected in 49% of patients (n 5 42) . Of them, 12%(n 5 5) of patients had a finding that wasidentified only by advanced features—including tumor-normal match, RNA sequencing, and/or liquid biopsy reflex testing—and may have been missed by the existing in-network NGS options. In the expanded cohort, potentially actionable alterations were detected in 31%(n 5 146) of patients. Of them, 12%(n 5 17) had findings identified solely by advanced features, including three patients enrolled in clinical trials. |\n| CONCLUSION | This study indicates that the CGP expanded treatment options in both the pilot and expanded cohort, with improvements directly attributable to specific features like tumor-normal matching, liquid biopsy reflex ordering, RNA sequencing, and Just-in-Time clinical trial matching. |\n\nACCOMPANYING CONTENT  \n Appendix  \nAccepted January 22, 2026 Published March 9, 2026  \nJCO Precis Oncol 10:e2500623 © 2026 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nASCO issued a provisional clinical opinion in 2022 recommending that patients with metastatic and advanced cancer receive next-generation sequencing (NGS) testing when the cancer type has one or more genomic biomarkers linked to an US Food and Drug Administration (FDA)–approved therapy.1 However, while advocating for NGS testing, the opinion refrained from providing explicit guidance on details such asthe composition of the NGS panel, panel size, and use of RNA sequencing and/or normal-matched sequencing. Additionally, the definition of actionable varies among physicians and different testing panels.2  \nTests with varying features may fall under the umbrella term comprehensive genomic profiling (CGP; alternatively, comprehensive molecular profiling [CMP]), and the extent to which specific features enhance patient care in community oncology settings remains ambiguous. Consequently, patients may face limitations with in-network testing options that might not offer a genuinely comprehensive evaluation. Our study assesses how particular features of a CGP panel influence the detection of clinically relevant or actionable findings and subsequently affect patient care.  \nTumor-normal matched sequencing can improve accuracy of somatic variant calling by 28%,3 improve tumor mutational  \n[ascopubs.org/journal/po](ascopubs.org/journal/po | 1)[ |](asco","cbCaiphp3kLEubvA","https://ap.wps.com/l/cbCaiphp3kLEubvA","pdf",1860412,13,"English","# Abstract\n## Purpose\n## Materials and Methods\n## Results\n## Conclusion\n# Introduction\n## Clinical and Knowledge Context\n## Objective and Key Knowledge Generated\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance","[{\"question\":\"Why is comprehensive genomic profiling (CGP) considered important for cancer treatment?\",\"answer\":\"CGP is advocated to tailor precision-guided therapies for patients with cancer. It helps identify genomic biomarkers linked to FDA-approved treatments.\"},{\"question\":\"How did the study assess the impact of CGP panel features?\",\"answer\":\"The study used a pilot pan-cancer cohort receiving NGS-based CGP and an expanded analysis of de-identified patient records. It evaluated potentially actionable findings, including those detected only by advanced features.\"},{\"question\":\"Which advanced CGP features contributed to improved detection of actionable findings?\",\"answer\":\"Tumor-normal matching, RNA sequencing, and liquid biopsy reflex testing were identified as key features that found actionable alterations not detected by existing in-network NGS options.\"}]","Unique Features of a Comprehensive Genomic Profiling Panel - Expanding Treatment Options in a Value-Based Community Oncology Network - Original Reports - Precision Medicine | PDF",1790148675,33]